Biotech RadarJobs updated

COMPANY

Cantex Pharmaceuticals

HQ: Weston, FL source · cantex.com ↗ · Southeast

Clinical Phase 2

Cantex Pharmaceuticals is listed on ClinicalTrials.gov as the lead sponsor of 4 studies; the most recently updated is “Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma” (Phase 1, Phase 2, completed), in Glioblastoma. From public records Source · Oct 12, 2026

Keywords: Glioblastoma Metastatic Pancreatic Cancer Recurrent Glioblastoma

Location: Weston, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Azeliragon in MGMT Unmethylated Glioblastoma source ↗
  2. Trial start Phase 1/Phase 2: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma source ↗
  3. Trial start Phase 1/Phase 2: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer source ↗
  4. Trial start Phase 2: Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05635734Azeliragon and Chemoradiotherapy in Newly Diagnosed GlioblastomaPhase 1/Phase 2CompletedSep 5, 2023Apr 30, 2026 (actual)
NCT05986851Azeliragon in MGMT Unmethylated GlioblastomaPhase 2Active, not recruitingSep 12, 2023Sep 30, 2026 (estimated)
NCT05766748Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic CancerPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Jun 1, 20232025-02 (estimated)
NCT03034135Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent GlioblastomaPhase 2CompletedMar 9, 2017Jul 10, 2018 (actual)
Feedback